Harrow (NASDAQ:HROW) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Harrow (NASDAQ:HROW) announced its quarterly earnings data on Thursday. The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.14, Zacks reports. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%.

Harrow Price Performance

NASDAQ:HROW opened at $27.87 on Friday. Harrow has a 52 week low of $9.86 and a 52 week high of $59.23. The stock’s fifty day moving average is $29.05 and its two-hundred day moving average is $38.10. The company has a market capitalization of $992.59 million, a P/E ratio of -29.65 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23.

Wall Street Analysts Forecast Growth

HROW has been the subject of a number of recent research reports. B. Riley cut their target price on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research note on Wednesday, December 4th. HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Harrow in a research report on Tuesday, March 18th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.